Relationship between Progression-Free Survival and Overall Survival in Chronic Lymphocytic Leukemia

Beauchemin, C.; Johnston, James B.; Lapierre, M.; Aïssa, F.; Lachaine, J.

doi:10.1016/s0923-7534(20)33669-3

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, no overall survival (OS) data were obtained. Even though PFS was widely accepted as an adequate surrogate and even more meaningful than OS [43,44], OS 8 remains important for efficacy prediction. Another limitation is the absence of a control group to control for confounding from external factors.…”

Section: Discussionmentioning

confidence: 99%

Apatinib Monotherapy as a Second-Line Treatment for Patients with Advanced Biliary Tract Cancer: a Retrospective Single-Center Observational Study

2019

Journal of Cancer Research and Therapeutic Oncology

View full text Add to dashboard Cite

Biliary tract cancer is an aggressive gastrointestinal malignancy with a dismal prognosis. Combined chemotherapy with gemcitabine and cisplatin is the gold standard of first-line treatment for patients with advanced biliary tract cancer, while second-line therapy remains inconclusive. We aimed to evaluate the effects of apatinib as a second-line regimen in patients with advanced biliary tract cancer. We retrospectively analyzed 18 patients with advanced biliary tract cancer who failed first-line therapy with gemcitabine alone or gemcitabine combined with cisplatin and received second-line treatment with apatinib from June 2016 to October 2017. Adverse events, progression-free survival, objective response rate, and disease control rate were documented and evaluated. All patients were followed up until progression of the disease.All patients were included in the efficacy analysis, including 6 drop-out cases. The 1-month tumor response assessment showed an objective response rate of 33% and a disease control rate of 72%. At a 6-month follow-up, a disease control rate of 44% was observed. The cohort achieved a median progression-free survival of 8 months; for gallbladder carcinoma of 2.5 months; for cholangiocarcinoma of 8 months. Fatigue, hypertension, and proteinuria were the most frequently occurring apatinib-related toxicities. Nine cases of grade 3 adverse effects were recorded, and no bleeding cases or treatment-related death were observed. This retrospective analysis showed favorable outcome and manageable toxicities of apatinib treatment in a second-line setting in patients with advanced biliary tract cancer. Perspective studies are needed to confirm the results from this study.

show abstract

Section: Discussionmentioning

confidence: 99%

Apatinib Monotherapy as a Second-Line Treatment for Patients with Advanced Biliary Tract Cancer: a Retrospective Single-Center Observational Study

2019

Journal of Cancer Research and Therapeutic Oncology

View full text Add to dashboard Cite

show abstract

“…The primary endpoint was PFS, which was defined as the time from the date of randomization to the date of documented disease progression or death. 18 Progression was defined according to the Response Evaluation Criteria in Solid Tumors version 1.1. Imaging was performed every 6 weeks and was analyzed at each participating center.…”

Section: Discussionmentioning

confidence: 99%

“…19 Time to progression (TTP) was calculated as the time from randomization to objective tumor progression, but cancer death was not included. 18 The lung cancer symptom scale was used to evaluate the health-related quality of life and functional dimensions of life. 20 The proportions of patients with cancer with measurable lesions achieving a response were assessed according to Response Evaluation Criteria in Solid Tumors version 1.1.…”

Section: Discussionmentioning

confidence: 99%

Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung — A Multicenter, Open-label, Randomized, Phase III Trial

Lü

Chen

Zhang

et al. 2018

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

“…Important clinical endpoints in assessing treatments for CLL include OS, PFS and quality of life (QoL). 11 The time to next treatment (TTNT) is also a relevant endpoint as it represents the time patients are off therapy and may have the freedom to work or travel. The longer the TTNT, the greater the positive impact on patients QoL as well as the greater chance a patient may have to access novel agents that will likely become available in the future.…”

Section: Cll11 Trialmentioning

confidence: 99%

Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil

Tam

Kuss

Opat

et al. 2017

Internal Medicine Journal

View full text Add to dashboard Cite

Patients with chronic lymphocytic leukaemia (CLL) are generally older, with many considered 'unfit' for fludarabine-cyclophosphamide-rituximab therapy. In these patients, the combination of obinutuzumab-chlorambucil may be an appropriate therapeutic choice. Obinutuzumab-chlorambucil has been demonstrated to improve overall survival rates compared to chlorambucil alone and to improve progression-free survival and overall response rates compared to rituximab-chlorambucil. This combination can lead to certain toxicities that need to be addressed through appropriate patient selection, pre-medication and management. In this paper, we discuss evidence-based and author-recommended practical management of first-line CLL patients receiving obinutuzumab-chlorambucil.

show abstract

Relationship between Progression-Free Survival and Overall Survival in Chronic Lymphocytic Leukemia

Cited by 3 publications

References 0 publications

Apatinib Monotherapy as a Second-Line Treatment for Patients with Advanced Biliary Tract Cancer: a Retrospective Single-Center Observational Study

Apatinib Monotherapy as a Second-Line Treatment for Patients with Advanced Biliary Tract Cancer: a Retrospective Single-Center Observational Study

Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung — A Multicenter, Open-label, Randomized, Phase III Trial

Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil

Contact Info

Product

Resources

About